Rimonabant is a small molecule medicine that was approved for the treatment of obesity and later withdrawn. ChEMBL records its first approval in 2006, a route by mouth, and a withdrawn flag, and the WHO Anatomical Therapeutic Chemical Index classifies it as A08AX01, among the other antiobesity drugs of the alimentary tract and metabolism group. The approved indication recorded for it is obesity. It is not on the World Health Organization Model List of Essential Medicines, 24th list, from 2025. Acomplia is a brand name under which it was marketed. Its record is a useful example of a medicine that reached approval and was then removed from use.
Facts
Classification
Approval Status ATC ClassA: Alimentary Tract and Metabolism 2 Route of Administration First Approved / Isolated Year Connections
Treats
Source ChEMBL, EMBL-EBI: Rimonabant approved indications (ChEMBL)
Sources
1. Rimonabant (ChEMBL record)
ChEMBL molecule record, first_approval
"first_approval": 2006
ChEMBL molecule record, maximum phase and withdrawn flag
"withdrawn_flag": true
ChEMBL molecule record, oral flag
"oral": true
View the Source2. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index: the WHO ATC/DDD Index entries named Rimonabant
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD IndexATC/DDD Index entry; ATC class derived from cited code A08AX01 (main group A)Quote, ATC/DDD Index entry; ATC class derived from cited code A08AX01 (main group A)
A08AX01 rimonabant
ChEMBL, EMBL-EBI: Rimonabant approved indications (ChEMBL)
ChEMBL, EMBL-EBITreats: Obesity, drug_indication record, maximum phase 4, MeSH heading ObesityQuote, Treats: Obesity, drug_indication record, maximum phase 4, MeSH heading Obesity
"max_phase_for_ind": "4.0", "mesh_heading": "Obesity", "molecule_chembl_id": "CHEMBL111"
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.